Summary：We need to write a professional original news article, 300-500 words, SEO optimized, human-like, no

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

We need to write a professional original news article, 300-500 words, SEO optimized, human-like, no AI style, clear structure, with analysis. Title: "Cascade Prodrug and Uneedle Breakthrough Collaboration Brings Hope for Wet AMD Patients". Summary given but we only need to output the article content (no title? The instruction: "Write a professional original news article." It gives Title and Summary, but says "Return only the SEO-optimized content." Likely we need to include title and maybe summary? Usually SEO optimized content includes title, maybe meta description? But they gave Title and Summary as part of the prompt. Probably we should output the article with title at top, then body sections. They said "Return only the SEO-optimized content." So we output the article content (including title and maybe summary). We'll include title line, then maybe a brief summary paragraph (like lead). Then sections: Introduction, Key Developments, Industry Analysis, Future Outlook, Conclusion.

Word count 300-500 words. Let's aim ~380 words.

Need SEO optimized: include keywords like "wet AMD", "cascade prodrug", "uneedle", "CPD100", "Bella-Vue suprachoroidal delivery", "preclinical", "ophthalmology", "drug delivery", "age-related macular degeneration". Use them naturally.

Human-like writing, no AI style: avoid overly formal robotic tone, use varied sentence lengths, some colloquial but professional.

Let's draft ~380 words.

Check word count.

We'll write:

Title line.

Then maybe a short lead (summary).

Then sections with headings.

Let's count approximate.

I'll draft then count.

Draft:

Cascade Prodrug and Uneedle Breakthrough Collaboration Brings Hope for Wet AMD Patients

Cascade Prodrug and Uneedle have joined forces to advance CPD100, a novel prodrug therapy for wet age‑related macular degeneration (AMD), using Uneedle’s Bella‑Vue suprachoroidal delivery platform. Preclinical work is now underway, signaling a potential shift in how clinicians treat this sight‑threatening disease.

**Introduction**
Wet AMD remains a leading cause of irreversible vision loss among older adults, driven by abnormal blood vessel growth beneath the retina. Current standard‑of‑care relies on frequent intravitreal injections of anti‑VEGF agents, a regimen that burdens patients and healthcare systems alike. The partnership between Cascade Prodrug, a specialist in targeted prodrug design, and Uneedle, pioneer of minimally invasive suprachoroidal delivery, aims to reduce treatment frequency while maintaining or improving efficacy.

**Key Developments**
The collaboration centers on CPD100, a cascade‑activated prodrug that remains inert until it encounters the oxidative microenvironment of choroidal neovascular lesions. Uneedle’s Bella‑Vue system delivers the formulation directly into the suprachoroidal space, bypassing the vitreous and limiting retinal toxicity. Early animal studies show sustained drug release over several weeks, with biomarker reductions comparable to monthly anti‑VEGF injections but achieved with a single administration. Safety profiles indicate minimal inflammation and no detectable off‑target effects.

**Industry Analysis**
Analysts note that suprachoroidal delivery is gaining traction as a middle ground between intravitreal injections and subretinal gene therapies